509 related articles for article (PubMed ID: 30449681)
21. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.
Berkan-Kawińska A; Piekarska A
Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714
[No Abstract] [Full Text] [Related]
22. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
Argyrou C; Moris D; Vernadakis S
J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
[TBL] [Abstract][Full Text] [Related]
23. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
Takaki Y; Saito Y; Takasugi A; Toshimitsu K; Yamada S; Muramatsu T; Kimura M; Sugiyama K; Suzuki H; Arai E; Ojima H; Kanai Y; Saito H
Cancer Sci; 2014 Oct; 105(10):1254-60. PubMed ID: 25117675
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
[TBL] [Abstract][Full Text] [Related]
25. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
Koyama N; Yamazaki T; Kanetsuki Y; Hirota J; Asai T; Mitsumoto Y; Mizuno M; Shima T; Kanbara Y; Arai S; Miyazaki T; Okanoue T
J Gastroenterol; 2018 Jun; 53(6):770-779. PubMed ID: 29086016
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.
Michael C; Martínez-Navarro FJ; de Oliveira S
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465
[TBL] [Abstract][Full Text] [Related]
27. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
[TBL] [Abstract][Full Text] [Related]
28. Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.
Zhang Y; Wang H; Xiao H
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065108
[TBL] [Abstract][Full Text] [Related]
29. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma.
Sadler EM; Mehta N; Bhat M; Ghanekar A; Greig PD; Grant DR; Yao F; Sapisochin G
Transplantation; 2018 Apr; 102(4):640-647. PubMed ID: 29319620
[TBL] [Abstract][Full Text] [Related]
30. Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma.
Dechassa ML; Tryndyak V; de Conti A; Xiao W; Beland FA; Pogribny IP
Mol Carcinog; 2018 Aug; 57(8):978-987. PubMed ID: 29603380
[TBL] [Abstract][Full Text] [Related]
31. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
Stine JG; Wentworth BJ; Zimmet A; Rinella ME; Loomba R; Caldwell SH; Argo CK
Aliment Pharmacol Ther; 2018 Oct; 48(7):696-703. PubMed ID: 30136293
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
33. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights.
Qin J; Higashi T; Nakagawa S; Fujiwara N; Yamashita YI; Beppu T; Baba H; Kobayashi M; Kumada H; Gunasekaran G; Schiano TD; Thung SN; Fiel MI; Hoshida Y; Ward SC
Am J Surg Pathol; 2020 Oct; 44(10):1406-1412. PubMed ID: 32618599
[TBL] [Abstract][Full Text] [Related]
34. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; Ji P; French B; Tillman B; French SW
Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
[TBL] [Abstract][Full Text] [Related]
35. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
36. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
37. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
[No Abstract] [Full Text] [Related]
38. A researcher's guide to preclinical mouse NASH models.
Gallage S; Avila JEB; Ramadori P; Focaccia E; Rahbari M; Ali A; Malek NP; Anstee QM; Heikenwalder M
Nat Metab; 2022 Dec; 4(12):1632-1649. PubMed ID: 36539621
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the Cell Death Pathway in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocarcinogenesis Is Associated with Histone H4 lysine 16 Deacetylation.
de Conti A; Dreval K; Tryndyak V; Orisakwe OE; Ross SA; Beland FA; Pogribny IP
Mol Cancer Res; 2017 Sep; 15(9):1163-1172. PubMed ID: 28512251
[TBL] [Abstract][Full Text] [Related]
40. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K; Uto H; Mawatari S; Ido A
Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]